NCT02690558View on ClinicalTrials.gov

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 6, 2020

Study Completion Date

January 30, 2026

Conditions
Bladder Cancer
Interventions
DRUG

pembrolizumab, gemcitabine and cisplatin

neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy

Trial Locations (2)

27599

North Carolina Cancer Hospital (UNC), Chapel Hill

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02690558 - Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | Biotech Hunter | Biotech Hunter